Search results

Clifford Chance advised Korian S.A. and its German subsidiary, Korian Deutschland AG, on its strategic partnership with Curanum AG and public takeover offer for all of its shares. Curanum AG is a listed German operator of senior residences and care facilities. Korian...

Le cabinet d'avocats international Clifford Chance a conseillé Biomnis, sous contrôle des fonds Duke Street depuis 2008, dans le cadre du refinancement de l'ensemble de sa dette bancaire senior et mezzanine pour un montant total de 150 millions d'euros.     ...

Leading international law firm Clifford Chance has advised Pfizer Inc. on its pharmaceutical manufacturing and distribution joint venture with Zhejiang Hisun Pharmaceutical, a leading pharmaceutical company in China listed on the Shanghai Stock Exchange. The companies...

Amsterdam, 28 June 2011 - the Amsterdam office of international law firm Clifford Chance has appointed five associates to counsel: Sylvia van der Heyden, Gijs Kikkert, Line Poliquin, Jan-Joost van Rijsbergen and Steven Verschuur. Bas Boris Visser, managing...

Le cabinet d'avocats d'affaires international Clifford Chance annonce sa collaboration avec Cegedim Relationship Management, expert mondial des solutions de conformité règlementaire pour le secteur des sciences de la vie. A travers cette collaboration, Cegedim...

Leading international law firm Clifford Chance is advising European private equity firm, Cinven on its acquisition of Mercury Pharma, the international speciality pharmaceutical company, for £465 million. Mercury markets niche and branded pharmaceuticals, with...

Clifford Chance advised Bayer HealthCare AG on the sale of a portfolio of molecular imaging substances from Bayer Pharma AG. The buyer is Piramal Imaging SA, a subsidiary of Piramal Healthcare Ltd. The portfolio sold comprises all PET tracer substances developed...

Leading international law firm Clifford Chance is advising Deutsche Bank on the restructuring and sale of the Swiss drug maker to Watson Pharmaceuticals for up to €4.5 billion ($5.9 billion). The Clifford Chance team is being led by Corporate partners Mark Poulton...

Amgen, Inc. and Micromet, Inc. announced today that the companies have entered into a definitive merger agreement under which Amgen will acquire Micromet, a biotechnology company founded in Germany with its research and development center in Munich and headquarters...

Clifford Chance advised Montagu Private Equity, London, on the sale of BSN medical to EQT VI. The purchase price amounts to approx. EUR 1.8 billion. The transaction is subject to statutory regulatory clearances. BSN medical, one of the world’s leading suppliers...